Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: ProteoMetrics in Acquisition Talks with Genomic Solutions

NEW YORK, July 30 - ProteoMetrics said Monday that it is currently in acquisition talks with Genomic Solutions.

"We're exploring a number of different business opportunities and an acquisition is one of them," said Jennifer Krone, vice president of scientific services at ProteoMetrics.

Under the terms of the agreement,  Genomic Solutions of Ann Arbor, Mich., has a first right of refusal to acquire New York-based Proteometrics, the companies said in a joint statement. Krone said ProteoMetrics has entered a 60-day quiet period during which it may not discuss other acquisitions but can go forward with other original equipment manufacturer deals.

Genomic Solutions was not available for comment.

The two companies announced earlier in the day that they plan to jointly develop a software product that merges Genomic Solutions’ Investigator Protein Warehouse data integration software with ProteoMetrics’ Radars mass spectrometry analysis system.

Genomic Solutions will also market ProteoMetrics' Knexus, Profound, and Sonar MS/MS software products. 

Krone declined to comment on whether Genomic Solutions had made an equity investment in ProteoMetrics.

Jeffrey Williams, CEO of Genomic Solutions, said in a statement that the partnership "will bring powerful new features and advantages to our existing Protein Warehouse software and enhance integration of our total Investigator Proteomic System with mass spectrometers from the leading vendors." 

This is the second bioinformatics partnership Genomic Solutions has entered recently. On July 19, the company said it was working with Atlanta-based NuTec Sciences to develop microarray analysis software for its GeneTac microarray system.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.